The JoPIC is an independent-unbiased, peer-reviewed, and open-access journal of current national and international issues and reviews for original clinical and experimental research, interesting case reports, surgical techniques, differential diagnoses, editorial opinions, letters to the editor, and educational papers in pulmonology, thoracic surgery, occupational diseases, allergology, and intensive care medicine. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

EndNote Style
Original Article
Diagnostic and prognostic value of serum amiloid a in patients with idiopatic pulmonary fibrosis
Aims: the aim of our study was to investigate the diagnostic and prognostic value of SAA and its usability as a biomarker in patients with IPF.
Methods: This study has been designed as a prospective, case-control study. Fifteen healthy individuals and 15 IPF patients. The demographic data and the measures from PFT, DLCO, laboratory tests of the patients included in the study were retrieved from IPF follow-up files.
Results: The comparison of the IPF patient group with the group of healthy volunteers revealed significantly higher SAA values in IPF patients (p:0.005). A significant positive correlation was found between the patients' SAA and C-Reactive Protein (CRP) values. A negative significant correlation was found between the SAA values of the patients and the time to diagnosis (p<0.05). Despite the negative correlation between the SAA and FVC values of patients, no significant correlations were detected between these variables (p>0.05). This result suggests that SAA levels would be higher in newly or recently diagnosed .
Conclusion: This study shows that SAA is significantly higher in IPF patients, suggesting that it will be a reliable biomarker feasible to predict the diagnosis. Future studies with larger patient groups ara needed.

1. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathicpulmonary fibrosis. an official ATS/ERS/JRS/ALAT clinical practiceguideline. Am J Respir Crit Care Med. 2018;198(5):e44-e68.
2. Yan F,Wen Z, Wang R, et al. Identification of the lipid biomarkers fromplasma in idiopathic pulmonary fibrosis by lipidomics. BMC PulmonaryMed. 2017;17(1):174.
3. Carleo A, Bargagli E, Landi C, et al. Comparative proteomic analysisof bronchoalveolar lavage of familial and sporadic cases of idiopathicpulmonary fibrosis. J Breath Res. 2016;10(2):026007.
4. Vietri L, Bennett D, Cameli P, et al. Serum amyloid A in patients withidiopathic pulmonary fibrosis. Respir Invest. 2019;57(5):430-434.
5. Bargagli E, Magi B, Olivieri C, Bianchi N, Landi C, Rottoli P. Analysis ofserum amyloid A in sarcoidosis patients. Respir Med. 2011;105(5):775-780.
6. Lin TL, Chen WW, Ding ZR, Wei SC, Huang ML, Li CH. Correlationsbetween serum amyloid A, C-reactive protein and clinical indices ofpatients with acutely exacerbated chronic obstructive pulmonary disease.J Clin Labor Analysis. 2019;33(4):e22831.
7. Lakota K, Carns M, Podlusky S, et al. Serum amyloid A is a markerfor pulmonary involvement in Systemic sclerosis. PloS One.2015;10(1):0110820.
8. Collard HR, Tino G, Noble PW, et al. Patient experiences with Pulmonaryfibrosis. Respir Med. 2007;101(6):1350-1354.
9. Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M, Vancheri C.Effect of pirfenidone on proliferation, TGF-&Beta;-induced myofibroblastdifferentiation and fibrogenic activity of primary human lung fibroblasts.Eur J Pharmaceut Sci. 2014;58:13-19.
10. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients withIdiopathic pulmonary fibrosis (CAPACITY): two randomised trials.Lancet. 2011;377(9779):1760-1769.
11. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosinekinase inhibitor in idiopathic pulmonary fibrosis. New Engl J Med.2011;365(12):1079-1087.
12. Mulhall A. INPULSIS Trial investigators. Efficacy and safety ofNintedanib in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med.2015;192(2):249-250.
13. Vietri L, Fui A, Bergantini L, et al. Serum amyloid A: a potentialbiomarker of lung disorders. Respir Invest. 2020;58(1):21-27.
14. Guiot J, Moermans C, Henket M, Corhay JL, Louis R. Blood biomarkersin Idiopathic pulmonary fibrosis. Lung. 2017;195(3):273-280.
15. Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathicpulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2014;307(9):L681-L691.
16. Lamas DJ, Kawut SM, Bagiella E, Philip N, Arcasoy SM, Lederer DJ.Delayed access and survival in idiopathic pulmonary fibrosis: a cohortstudy. Am J Respir Crit Care Med. 2011;184(7):842-847.
17. Lancaster L, Albera C, Bradford WZ, et al. Safety of pirfenidone in patientswith idiopathic pulmonary fibrosis: integrated analysis of cumulative datafrom 5 clinical trials. BMJ Open Respir Res. 2016;3(1):e000105.
18. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathicpulmonary fibrosis. Eur Respir J. 2010;35(4):821-829.
19. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanibin idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-2082.
20. Patel H, Fellowes R, Coade S, Woo P. Human serum amyloid A hascytokine-like properties. Scand J Immunol. 1998;48(4):410-418.
Volume 2, Issue 1, 2024
Page : 1-5